The use of SSA in monotherapy could be considered when Ki67 < 20 %, when there is low tumor load, and in case of important comorbidities, since SSA results mainly in tumor stabilization, and has low toxicity [34, 46, 60]. This evidence concerns the gene MKI67 and neoplasm.